News | August 06, 2013

Vanderbilt Heart Participates in Study of New Rapid Cooling Technology to Reduce Heart Damage

Investigational study of Velomedix is for patients with acute myocardial infractions

August 6, 2013 — Vanderbilt Heart and Vascular Institute is participating in the VELOCITY study, a randomized controlled clinical study to assess the safety and feasibility of a rapid cooling system for heart attack patients that could minimize damage to the heart.

Vanderbilt is one of six sites in the United States and Canada, and it is the only one in Tennessee, to offer this study of the Velomedix rapid therapeutic hypothermia system in patients with acute myocardial infarctions (AMIs, also known as heart attacks).

Vanderbilt Heart has already enrolled two patients in this investigational study, which will include up yo 60 patients with a severe form of AMI, called ST-segment elevation myocardial infarction (STEMI). Participants in the study are randomized to one of two arms. Patients in the control arm receive the current standard treatment for STEMI, namely percutaneous coronary intervention (PCI) without therapeutic hypothermia. During this treatment, the physician reopens the blocked blood vessel and returns blood flow to the affected region.

Patients in the treatment arm are rapidly cooled first to a temperature of less than 35°C (95°F) just before receiving the same PCI treatment. The Velomedix system circulates cold fluid throughout the patient’s body to achieve the lower temperature.

To be considered for the study, potential candidates must meet the following criteria:

  • Must be 18 to 85 years of age
  • Having STEMI (? 2mm)
  • Arrive at Vanderbilt within six hours of the start of symptoms
  • Have no previous myocardial infarction
  • Currently not be on dialysis treatment
  • Able to undergo magnetic resonance imaging (MRI) scans
  • Must be willing to return for a follow-up exam including a second MRI scan approximately 30 days after initial treatment


“In three previous studies, we have seen that if a patient is cooled to below 35°C prior to reopening the blocked coronary artery, the size of the heart attack may be reduced substantially,” said Gregg Stone, M.D., of Columbia University Medical Center / New York-Presbyterian Hospital and co-principal investigator of the VELOCITY study. “The cooling approach in this study may prove to be effective in cooling patients fast enough to provide benefit without significantly delaying reperfusion.”

For more information: www.clinicaltrials.gov

Related Content

New Multi-Center Research Effort to Focus on Early Life Origins of Heart Health
News | Congenital Heart| June 23, 2017
Heart health in children will be the focus of three closely synergistic research projects and an integrated...
Sponsored Content | Videos | Angiography| June 22, 2017
Shimadzu Medical Systems hghlighted new features of its Trinias Interventional X-ray line at the America College of C
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
BioImage-2 Study to Investigate Atherosclerotic Disease Progression
News | Cardiovascular Ultrasound| June 20, 2017
Mount Sinai Heart and BioImage-2 LLC recently announced the start of the BioImage-2 study investigating the progression...
Stroke2prevent Receives FDA 510(k) Clearance for A-View
Technology | Ultrasound Transesophageal echo (TEE)| June 20, 2017
June 20, 2017 — Dutch medical device company Stroke2prevent BV recently announced it has received U.S.
IABP recall for Maquet, Datascope intra-aortic balloon pump CS100 and CS300

The Datascope CS300 IABP console.

News | Hemodynamic Support Devices| June 20, 2017
June 20, 2017 — The U.S.
Sponsored Content | Videos | Cardiovascular Ultrasound| June 15, 2017
Madhav Swaminathan, M.D., FASC, FAHA, clinical director of cardiothoracic anesthesiology, at Duke Univer
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Overlay Init